These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 26132001)
1. Glycosylation Analysis for Congenital Disorders of Glycosylation. Li X; Raihan MA; Reynoso FJ; He M Curr Protoc Hum Genet; 2015 Jul; 86():17.18.1-17.18.22. PubMed ID: 26132001 [TBL] [Abstract][Full Text] [Related]
2. Mass spectrometry of transferrin glycoforms to detect congenital disorders of glycosylation: Site-specific profiles and pitfalls. Wada Y Proteomics; 2016 Dec; 16(24):3105-3110. PubMed ID: 27095603 [TBL] [Abstract][Full Text] [Related]
3. MALDI-MS profiling of serum O-glycosylation and N-glycosylation in COG5-CDG. Palmigiano A; Bua RO; Barone R; Rymen D; Régal L; Deconinck N; Dionisi-Vici C; Fung CW; Garozzo D; Jaeken J; Sturiale L J Mass Spectrom; 2017 Jun; 52(6):372-377. PubMed ID: 28444691 [TBL] [Abstract][Full Text] [Related]
4. MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. Comparison with two-dimensional electrophoresis. Yen-Nicolaÿ S; Boursier C; Rio M; Lefeber DJ; Pilon A; Seta N; Bruneel A Proteomics Clin Appl; 2015 Aug; 9(7-8):787-93. PubMed ID: 25641685 [TBL] [Abstract][Full Text] [Related]
5. Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. Xia B; Zhang W; Li X; Jiang R; Harper T; Liu R; Cummings RD; He M Anal Biochem; 2013 Nov; 442(2):178-85. PubMed ID: 23928051 [TBL] [Abstract][Full Text] [Related]
6. Increased Clinical Sensitivity and Specificity of Plasma Protein Chen J; Li X; Edmondson A; Meyers GD; Izumi K; Ackermann AM; Morava E; Ficicioglu C; Bennett MJ; He M Clin Chem; 2019 May; 65(5):653-663. PubMed ID: 30770376 [TBL] [Abstract][Full Text] [Related]
7. A Novel N-Tetrasaccharide in Patients with Congenital Disorders of Glycosylation, Including Asparagine-Linked Glycosylation Protein 1, Phosphomannomutase 2, and Mannose Phosphate Isomerase Deficiencies. Zhang W; James PM; Ng BG; Li X; Xia B; Rong J; Asif G; Raymond K; Jones MA; Hegde M; Ju T; Cummings RD; Clarkson K; Wood T; Boerkoel CF; Freeze HH; He M Clin Chem; 2016 Jan; 62(1):208-17. PubMed ID: 26430078 [TBL] [Abstract][Full Text] [Related]
8. Mass spectrometry for congenital disorders of glycosylation, CDG. Wada Y J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 838(1):3-8. PubMed ID: 16517226 [TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical characterization of a patient with congenital disorder of glycosylation (CDG) IIx. Miura Y; Tay SK; Aw MM; Eklund EA; Freeze HH J Pediatr; 2005 Dec; 147(6):851-3. PubMed ID: 16356446 [TBL] [Abstract][Full Text] [Related]
11. Insights into complexity of congenital disorders of glycosylation. Goreta SS; Dabelic S; Dumic J Biochem Med (Zagreb); 2012; 22(2):156-70. PubMed ID: 22838182 [TBL] [Abstract][Full Text] [Related]
12. The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation. Sturiale L; Barone R; Garozzo D J Inherit Metab Dis; 2011 Aug; 34(4):891-9. PubMed ID: 21384227 [TBL] [Abstract][Full Text] [Related]
13. A new strategy implementing mass spectrometry in the diagnosis of congenital disorders of N-glycosylation (CDG). Casetta B; Malvagia S; Funghini S; Martinelli D; Dionisi-Vici C; Barone R; Fiumara A; Donati MA; Guerrini R; la Marca G Clin Chem Lab Med; 2020 Aug; 59(1):165-171. PubMed ID: 32776892 [TBL] [Abstract][Full Text] [Related]
14. Characteristics of glycation and glycation sites of lysozyme by matrix-assisted laser desorption/ionization time of flight/time-of-flight mass spectrometry and Liquid chromatography-electrospray ionization tandem mass spectrometry. Ruan ED; Wang H; Ruan Y; Juáreza M Eur J Mass Spectrom (Chichester); 2014; 20(4):327-36. PubMed ID: 25420345 [TBL] [Abstract][Full Text] [Related]
15. A new method for the rapid diagnosis of protein N-linked congenital disorders of glycosylation. Heywood WE; Mills P; Grunewald S; Worthington V; Jaeken J; Carreno G; Lemonde H; Clayton PT; Mills K J Proteome Res; 2013 Jul; 12(7):3471-9. PubMed ID: 23742123 [TBL] [Abstract][Full Text] [Related]
16. Laboratory diagnosis of congenital disorders of glycosylation type I by analysis of transferrin glycoforms. Babovic-Vuksanovic D; O'Brien JF Mol Diagn Ther; 2007; 11(5):303-11. PubMed ID: 17963418 [TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-III O-glycoform profiling of 500 serum samples by matrix-assisted laser desorption/ionization mass spectrometry for diagnosis of congenital disorders of glycosylation. Wada Y; Okamoto N J Mass Spectrom; 2021 Apr; 56(4):e4597. PubMed ID: 32677746 [TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry of transferrin and apolipoprotein C-III for diagnosis and screening of congenital disorder of glycosylation. Wada Y Glycoconj J; 2016 Jun; 33(3):297-307. PubMed ID: 26873821 [TBL] [Abstract][Full Text] [Related]
19. Plasma N-glycan profiling by mass spectrometry for congenital disorders of glycosylation type II. Guillard M; Morava E; van Delft FL; Hague R; Körner C; Adamowicz M; Wevers RA; Lefeber DJ Clin Chem; 2011 Apr; 57(4):593-602. PubMed ID: 21273509 [TBL] [Abstract][Full Text] [Related]
20. Mass spectrometry glycophenotype characterization of ALG2-CDG in Argentinean patients with a new genetic variant in homozygosis. Papazoglu GM; Cubilla M; Pereyra M; de Kremer RD; Pérez B; Sturiale L; Asteggiano CG Glycoconj J; 2021 Apr; 38(2):191-200. PubMed ID: 33644825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]